派姆单抗单药治疗晚期升结肠癌的新辅助治疗成功

Journal of Cancer Research and Practice Pub Date : 2023-01-01 DOI:10.4103/ejcrp.ejcrp-d-23-00005

Chien-Tzu Huang, Jeng-Shiun Du

{"title":"派姆单抗单药治疗晚期升结肠癌的新辅助治疗成功","authors":"Chien-Tzu Huang, Jeng-Shiun Du","doi":"10.4103/ejcrp.ejcrp-d-23-00005","DOIUrl":null,"url":null,"abstract":"Immune checkpoint inhibitors have emerged as an effective standard of care for deficient mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC). However, the role of immunotherapy in the neoadjuvant setting remains uncertain. We report a patient with advanced colon cancer who received curative surgery after successful treatment with pembrolizumab monotherapy. She remains in complete remission after 16 months following the first diagnosis without any immune-related adverse events. In conclusion, single-agent pembrolizumab has strong potential in neoadjuvant therapy for patients with dMMR/MSI-H advanced CRC.","PeriodicalId":31219,"journal":{"name":"Journal of Cancer Research and Practice","volume":"11 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Successful neoadjuvant therapy with pembrolizumab monotherapy for advanced ascending colon cancer\",\"authors\":\"Chien-Tzu Huang, Jeng-Shiun Du\",\"doi\":\"10.4103/ejcrp.ejcrp-d-23-00005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Immune checkpoint inhibitors have emerged as an effective standard of care for deficient mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC). However, the role of immunotherapy in the neoadjuvant setting remains uncertain. We report a patient with advanced colon cancer who received curative surgery after successful treatment with pembrolizumab monotherapy. She remains in complete remission after 16 months following the first diagnosis without any immune-related adverse events. In conclusion, single-agent pembrolizumab has strong potential in neoadjuvant therapy for patients with dMMR/MSI-H advanced CRC.\",\"PeriodicalId\":31219,\"journal\":{\"name\":\"Journal of Cancer Research and Practice\",\"volume\":\"11 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Research and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ejcrp.ejcrp-d-23-00005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ejcrp.ejcrp-d-23-00005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

免疫检查点抑制剂已成为一种有效的标准护理缺陷错配修复(dMMR)/高微卫星不稳定性(MSI-H)转移性结直肠癌(CRC)。然而，免疫治疗在新辅助治疗中的作用仍然不确定。我们报告了一位晚期结肠癌患者，在接受派姆单抗单药治疗成功后接受了根治性手术。在第一次诊断后16个月，她仍然处于完全缓解状态，没有任何与免疫相关的不良事件。总之，单药派姆单抗在dMMR/MSI-H晚期结直肠癌患者的新辅助治疗中具有强大的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Successful neoadjuvant therapy with pembrolizumab monotherapy for advanced ascending colon cancer

Immune checkpoint inhibitors have emerged as an effective standard of care for deficient mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC). However, the role of immunotherapy in the neoadjuvant setting remains uncertain. We report a patient with advanced colon cancer who received curative surgery after successful treatment with pembrolizumab monotherapy. She remains in complete remission after 16 months following the first diagnosis without any immune-related adverse events. In conclusion, single-agent pembrolizumab has strong potential in neoadjuvant therapy for patients with dMMR/MSI-H advanced CRC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Cancer Research and Practice

自引率

0.00%

发文量

审稿时长

24 weeks

期刊介绍： JCRP aims to provide an exchange forum for the cancer researchers and practitioners to publish their timely findings in oncologic disciplines. The scope of the Journal covers basic, translational and clinical research, Cancer Biology, Cancer Immunotherapy, Hemato-oncology, Digestive cancer, Urinary tumor, Germ cell tumor, Breast cancer, Lung cancer, Head and Neck Cancer in a vast range of cancer related topics. The Journal also seeks to enhance and advance the cancer care standards in order to provide cancer patients the best care during the treatments.